Novartis' Signifor approved in EU for acromegaly patients

The European Commission has approved Swiss drug major Novartis’ (NOVN: VX) Signifor (pasireotide) for patients with acromegaly for whom surgery is not an option or has not been curative, and who are inadequately controlled on treatment with a first-generation somatostatin analogue (SSA).

Signifor is a long acting release formulation for once monthly intramuscular injection, which offers the first alternative treatment option directly targeting the pituitary tumor for patients whose acromegaly remains inadequately controlled on currently available SSAs.